Abemaciclib

Drug Profile

Abemaciclib

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; CDK 4/6 dual inhibitor - Eli Lilly; Cyclin dependent kinase 4/6 dual inhibitor - Eli Lilly; LY-2835219

Latest Information Update: 21 Jul 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Dana-Farber Cancer Institute; Eli Lilly; Emory University; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Non-small cell lung cancer
  • Phase II Brain cancer; Cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Pancreatic cancer
  • Preclinical Solid tumours

Most Recent Events

  • 13 Jul 2017 Phase-II clinical trials in Brain cancer (Recurrent, Second-line therapy or greater) in USA (PO) (NCT03220646)
  • 10 Jul 2017 Abemaciclib receives priority review status for Breast cancer (Second-line therapy or greater, Late-stage disease) in USA
  • 10 Jul 2017 Eli Lilly files NDA application with the US FDA for Breast cancer (Second-line therapy or greater, Late-stage disease) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top